History of EA Pharma Co., Ltd.
|
2016 |
EA Pharma Co., Ltd. inauguration. The Eisai Group's gastrointestinal disease business and the Ajinomoto Group's gastrointestinal disease business are integrated to establish EA Pharma Co., Ltd. The oral bowel cleansing agent "MOVIPREP® " wins "Good Design Award 2016". |
|---|---|
|
2017 |
An additional dosage and administration of proton pump inhibitor Pariet® 5 mg Tablets, 10 mg Tablets is approved in Japan. The ulcerative colitis treatment “RECTABUL® 2 mg Rectal Foam 14 Doses” is launched in Japan. |
|
2018 |
EA Pharma Co., Ltd. obtains the "medical device manufacturing license". The bile acid transporter inhibitor “GOOFICE® 5mg Tablet” is launched in Japan. The chronic constipation treatment "MOVICOL®" is launched in Japan. |
|
2019 |
The website "e-ben navi" to increase understanding about chronic constipation is launched. |
|
2021 |
Hidenori Yabune is appointed President & CEO |
History of Eisai Co., Ltd.
History of former Ajinomoto Pharmaceuticals Co., Ltd.
|
1956 |
Morishita Pharmaceutical Co., Ltd. launches MORIAMIN®, the world ’s first crystalline amino acid infusion solution. Ajinomoto Co., Inc. (the Company) begins production of pharmaceutical-use amino acids at its Kawasaki Plant, supplies to Morishita. |
|---|---|
|
1957 |
Capital participation in Morishita. |
|
1981 |
The Company develops and Morishita launches elemental diet ELENTAL®. |
|
1986 |
The Company develops and Morishita launches LENTINAN, an anti-tumor drug. |
|
1991 |
The Company develops and Morishita launches HEPAN ED®, an elemental diet for hepatic failure. |
|
1995 |
The Company develops and Roussel Morishita launches ATELEC®, a long-acting calcium channel blocker. |
|
1996 |
The Company develops and Hoechst Marion Roussel Japan Ltd. |
|
1999 |
The Company develops nateglinide, a fast-acting postprandial hypoglycemic agent, which is sold under the brand name FASTIC® by Hoechst Marion Roussel Ltd. and by Yamanouchi Pharmaceutical Co.,Ltd. under the brand name Starsis®. Overseas, the Company enters into a licensing agreement with Novartis AG of Switzerland, which begins sales under the name Starlix® in 2001. |
|
2002 |
The Company, Aventis Pharma Ltd. and Takeda Pharmaceutical Company Limited jointly develop risedronate, an osteoporosis treatment, for the Japanese market. The product is sold under the brand name Actonel® by Aventis and by Takeda under the brand name BENET®. |
|
2005 |
Ajinomoto Medica Co., Ltd.*2 is inaugurated. |
|
2008 |
AJINOMOTO NUTRITION FOODS Co., Ltd.*3 is inaugurated. |
|
2010 |
AJINOMOTO PHARMACEUTICALS CO., LTD.*4 is inaugurated. |
|
2012 |
Stock of AJINOMOTO NUTRITION FOODS Co., Ltd. is assigned to Ajinomoto Co., Inc. |
|
2013 |
An oral cleansing solution for intestine MOVIPREP®# launches. |
|
2014 |
AJINOMOTO PHARMACEUTICALS CO., LTD.develops and MOCHIDA PHARMACEUTICAL CO., LTD.launches ATEDIO®,a selective AT1 receptor blocker / long-acting calcium channel blocker. |
- *1 Ajinomoto Pharma Co., Ltd.
- The Company acquired the infusion and nutrition business of Hoechst Marion Roussel Japan Ltd. and inaugurated it as a wholly owned subsidiary.
- *2 Ajinomoto Medica Co., Ltd.
- A company formed by the merger of Shimizu Pharmaceutical Co., Ltd. with the Production Division (Saitama and Fukushima plants) and Distribution Division of Ajinomoto Pharma Co., Ltd. to handle production and distribution for the pharmaceuticals business.
- *3 AJINOMOTO NUTRITION FOODS Co., Ltd.
- A sales promotion company wholly owned by Ajinomoto Pharma Co., Ltd., established to develop the nursing care and home care markets and strengthen sales of medical foods. Ownership changed to 80% by the Company and 20% by AJINOMOTO PHARMACEUTICALS CO., LTD. in April 2010.It became a wholly owned subsidiary of Ajinomoto Co., Inc. in April 2012.
- *4 AJINOMOTO PHARMACEUTICALS CO., LTD.
- A company formed by the separation of the pharmaceuticals business of the Company and merger with Ajinomoto Pharma Co., Ltd. and Ajinomoto Medica Co., Ltd. It was inaugurated as a wholly owned subsidiary of the Company that handles research and development through to production and sales.
- *5 AY PHARMACEUTICALS CO., LTD.
- A spin-off of the infusion and dialysis business units of AJINOMOTO PHARMACEUTICALS CO., LTD., inaugurated as a joint venture between Yoshindo Inc. (51%) and AJINOMOTO PHARMACEUTICALS CO., LTD. (49%). It became a wholly owned subsidiary of Yoshindo Inc. in March 2016.
The company name are as of those times and may be different from the latest ones.
# MOVIPREP® is registered trademark of Norgine group.